Pando Bioscience, founded to revolutionize enzyme engineering in the pharmaceutical industry, leverages AI-driven synthetic biology to discover, optimize, and design high-value biological molecules. Their core mission is to enhance drug discovery by providing tailored enzymes that reduce costs and improve efficiency. Utilizing an ultra-high-throughput screening platform, Pando screens enzymes 1000-fold more efficiently and 75% faster than traditional methods, significantly cutting costs by 80%.

Notable figures associated with Pando Bioscience include experts in synthetic biology and AI, though specific names are not provided. The company has achieved significant milestones in reducing the time and cost of enzyme optimization, positioning itself as a leader in pharmaceutical innovation. By integrating generative AI with advanced screening techniques, Pando has made a substantial impact on the production of active pharmaceutical ingredients (APIs), driving forward the capabilities of modern therapeutics.